Thalomid

The FDA required that Celgene Corporation, which planned to market thalidomide under the brand name Thalomid, establish a System for Thalidomide Education and Prescribing Safety S.T.E.P.S oversight program.

The Volokh Conspiracy » Paternalism and Slippery Slopes 2009

Celgene Corp., a drug developer in Summit, N.J., won regulatory approval to sell the drug under the brand name Thalomid for a skin condition associated with leprosy.

Fast Growth 2007

Pharmion owns the European marketing rights to Celgene's thalidomide drug, Thalomid, which is used to treat myeloma, a bone-marrow cancer.

Celgene to Acquire Pharmion 2007

The maker of the drug, Celgene Corp., is making a nice little profit out of what is now called Thalomid; I blogged about this back in August last year, after it was revealed that Celgene was playing the bureaucratic game by not applying to have its drug approved for general use by Health Canada.

Archive 2006-03-01 2006

The maker of the drug, Celgene Corp., is making a nice little profit out of what is now called Thalomid; I blogged about this back in August last year, after it was revealed that Celgene was playing the bureaucratic game by not applying to have its drug approved for general use by Health Canada.

Death by bureaucrat 2006

One of their main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy.

Biotech Sector and Stocks Analysis from Seeking Alpha 2009

One of their main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy.

Healthcare Sector and Stocks Analysis from Seeking Alpha 2009

Thalomid sales dropped 16% to $91 million in the quarter.

Celgene Profit Drops 16% as Revenue Jumps Thomas Gryta 2011

Revlimid is a more potent derivative of thalidomide, which Celgene has sold as Thalomid since 1998.

Celgene Profit Drops 16% as Revenue Jumps Thomas Gryta 2011

Since 1998, for example, Celgene, a biotechnology company based in Summit, N.J., has raised the price of Thalomid, a drug for a cancer called multiple myeloma, to more than $35,000 a year from $4,000.

Democracy's Vices, Arnold Kling | EconLog | Library of Economics and Liberty 2009